1. Patient-centered outcomes at hospital discharge in mechanically ventilated COVID-19 patients in Kobe, Japan: A single-center retrospective cohort study.
- Author
-
Ito J, Kawakami D, Seo R, Iwata K, Ouchi K, Nonami S, Miyoshi Y, Tatebe M, Tsuchida T, Asaka Y, Takeda C, Nishihara H, Mima H, Doi A, Tomii K, and Ariyoshi K
- Subjects
- Adult, Aged, Critical Illness, Hospitals, Humans, Japan epidemiology, Middle Aged, Patient Discharge, Patient-Centered Care, Retrospective Studies, COVID-19 epidemiology, Respiration, Artificial
- Abstract
Background: Apart from saving the lives of coronavirus disease (COVID-19) patients on mechanical ventilation (MV), recovery from the sequelae of prolonged MV (PMV) is an emerging issue.c METHODS: We conducted a retrospective study among consecutive adult COVID-19 patients admitted to an intensive care unit (ICU) in Kobe, Japan, between March 3, 2020, and January 31, 2021, and received invasive MV. Clinical outcomes included in-hospital mortality and recovery from COVID-19 in survivors regarding organ dysfunction, respiratory symptoms, and functional status at discharge. We compared survivors' outcomes with MV durations of >14 days and ≤14 days., Results: We included 85 patients with a median age of 69 years (interquartile range, 64-75 years); 76 (89%) patients had at least 1 comorbidity, 72 (85%) were non-frail, and 79 (93%) were functionally independent before COVID-19 infection. Eighteen patients (21%) died during hospitalization. At discharge, 59/67 survivors (88%) no longer required respiratory support, 50 (75%) complained of dyspnea, and 40 (60%) were functionally independent. Of the survivors, 23 patients receiving MV for >14 days had a worse recovery from COVID-19 at discharge compared with those on MV for ≤14 days, as observed using the Barthel index (median: 35 [5-65] vs. 100 [85-100]), ICU mobility scale (8 [5-9] vs. 10 [10-10]), and functional oral intake scale (3 [1-7] vs. 7 [7-7]) (P < 0.0001)., Conclusion: Although four-fifths of the patients survived and >50% of survivors demonstrated clinically important recovery in organ function and functional status during hospitalization, PMV was related to poor recovery from COVID-19 at discharge., Competing Interests: Conflict of Interest KT received honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and GlaxoSmithKline. All other authors have no conflicts of interest to declare., (Copyright © 2022 [The Author/The Authors]. Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF